Results 251 to 260 of about 104,112 (336)

Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A/P‐gp Modulators

Clinical and Translational Science, Volume 18, Issue 10, October 2025.
ABSTRACT Valemetostat tosylate (valemetostat) is an oral, potent, selective dual inhibitor of enhancer of zeste homolog (EZH)2 and EZH1, approved in Japan for the treatment of relapsed/refractory adult T‐cell leukemia/lymphoma and peripheral T‐cell lymphoma.
Akiko Watanabe, Noriko Okudaira, Masaya Tachibana, Miho Kazui, Masakatsu Kotsuma, Takako Shimizu, Yvonne Lau   +6 more
wiley   +1 more source

Additive Therapeutic Effects of Topical Sirolimus Following Oral Propranolol Therapy for Kaposiform Hemangioendothelioma. [PDF]

Clin Cosmet Investig Dermatol
Xiu B, Xu Z, Xu Z, Zhang B, Wei L, Ma L.
europepmc   +1 more source

Molecular targeted treatment in infants with central conducting lymphatic anomalies. [PDF]

Eur J Pediatr
van den Brink VC, Kleimeier LER, Leenders EKSM, Klein WM, de Boode WP, Fuijkschot J, Vrancken SLAG.   +6 more
europepmc   +1 more source

Hyperhidrosis: don't sweat it

Internal Medicine Journal, Volume 55, Issue 10, Page 1626-1631, October 2025.
Abstract Hyperhidrosis is an under‐reported and under‐treated condition that causes significant patient morbidity. Secondary causes require consideration, but the vast majority of cases are idiopathic. The condition is encountered by a range of clinicians, including neurologists, dermatologists and endocrinologists, and it pays to be familiar with the ...
Mitchell J. Lycett, Karl Ng
wiley   +1 more source

Consumptive hypothyroidism complicating infantile hepatic hemangioma successfully treated with propranolol: a case report and literature review. [PDF]

Ital J Pediatr
Bettini I, Poletti G, Rocca A, Di Natale V, Gennari M, Lanari M, Pession A, Cassio A.   +7 more
europepmc   +1 more source

Effect of Propranolol on Cardiac Arrhythmias Induced by Adrenaline under Halothane Anesthesia

, 1966
K Iwatsuki, T Yusa, Isamu Yasuda, Yasuhiko Hashimoto, Kotaro Takahashi, Naofumi Iwatsuki   +5 more
openalex   +2 more sources

Silent Dangers in Elderly Pharmacotherapy: The Interplay of Polypharmacy, Multimorbidity, and Drug Interactions

Journal of Evaluation in Clinical Practice, Volume 31, Issue 7, October 2025.
ABSTRACT Background Pharmacological therapy in older persons is inherently complex due to the interplay of age‐related physiological changes, multimorbidity, and polypharmacy. These factors increase the vulnerability of elderly patients to drug interactions and adverse drug reactions.
N. N. Ngcobo
wiley   +1 more source

Impact of Underlying Portal Hypertension on Severity and Course of Acute‐On‐Chronic Liver Failure

Liver International, Volume 45, Issue 10, October 2025.
ABSTRACT Background and Aims The impact of portal hypertension (PH) during acute‐on‐chronic liver failure (ACLF) remains unclear. This study investigated the link between underlying PH severity, systemic inflammation (SI), and the course of ACLF. Methods Consecutive patients with ACLF (n = 192) who met the EASL‐CLIF criteria were retrospectively ...
Vlad Taru, Georg Kramer, Benedikt S. Hofer, Nina Dominik, Lorenz Balcar, Mathias Schneeweiss‐Gleixner, Bogdan Procopet, Michael Trauner, Mattias Mandorfer, Philipp Schwabl, Thomas Reiberger, Benedikt Simbrunner   +11 more
wiley   +1 more source

Sub-zero temperature biosolvent-assisted liquid-liquid microextraction for quantifying propranolol and carvedilol in human urine using HPLC-UV: greenness profile evaluation. [PDF]

RSC Adv
Nisyriou S, Zacharis CK.
europepmc   +1 more source

Flunitrazepam increases the risk of lamotrigine‐induced cutaneous adverse reactions: Combined analysis of medical big data and clinical research

Psychiatry and Clinical Neurosciences, Volume 79, Issue 10, Page 629-635, October 2025.
Aim The concomitant use of lamotrigine and valproic acid, a uridine diphosphate (UDP)‐glucuronosyltransferase inhibitor, is a known risk factor for lamotrigine‐induced rashes, which may develop into fatal or severe cutaneous adverse reactions. No drugs other than valproic acid have been shown to increase lamotrigine concentrations in humans by ...
Hiroshi Bando, Mitsuhiro Goda, Masahito Nakataki, Keita Hirai, Yuki Nitta, Kei Kawada, Toshihiko Yoshioka, Masaya Kanda, Atsushi Ogawa, Chiaki Mukuta‐Murakami, Kaito Tsujinaka, Koji Miyata, Kohei Kitagawa, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Yuki Izawa‐Ishizawa, Masayuki Chuma, Takafumi Naito, Yoshikazu Tasaki, Shusuke Numata, Keisuke Ishizawa   +21 more
wiley   +1 more source